Division of Cardiology

Koon Teo

MBBCH (National University of Ireland, RCSI), PhD (Alberta), FRCPC, FRCPI, FACC, FAHA

Professor, Division of Cardiology

Associate Member, Dept of Clinical Epidemiology & Biostatistics

Chief, Cardiology Service, McMaster University Medical Centre



Research Interests

Dr. Teo’s research interests are in clinical trials and epidemiology studies on cardiovascular diseases.  He is the principal investigator and in major studies supported by the CIHR and other funding agencies.  These include the FAMILY study and COURAGE trial. The FAMILY study has recruited and is following 859 families with 901 babies investigating the origins of atherosclerosis and cardiovascular risk factors in early life and the influences of environmental and genetic factors in shaping future cardiovascular disease. The COURAGE trial, of which he is the Canadian PI, showed that in individuals with stable coronary disease and angina, long term intensive medical therapy is as good coronary ballooning and stenting plus intensive medical therapy. This finding is having a large impact on the practice of cardiology. He is Co-Investigator for the PURE epidemiology study in 17 countries enrolling over 140,000 subjects studying the causes of cardiovascular risk factors in various societies and communities.

Selected Publications

  1. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavil V, Taylor D, Yokoyama S, Montague TJ, on behalf of the SCAT Investigators.  Long term effects of cholesterol lowering and angiotensin converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial. Circulation 2000;102:1748-1754.
  2. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GBJ, Berman DS, Weintraub WS, on behalf of the COURAGE Trial Co-Principal Investigators and Study Coordinators. Design of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial, VA Cooperative Study No. 424. (partial funding by CIHR) Am Heart J 2006;151:1173-1179.
  3. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R, Rashed W, Freeman R, Jiang L, Zhang X, Yusuf S.  Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART Study: a case-control study. Lancet 2006;368:647-658.
  4. The ONTARGET Investigators (writing group: Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
  5. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S. The PURE Investigators Writing Group.  The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle- and high-income countries. Am Heart J 2009;158: 1-7
  6. Morrison KM, Atkinson SA, Yusuf S, Bourgeois J, McDonald S, Persadie R, Hunter B, Pogue J, Teo K and the FAMILY Investigators. The Family Atherosclerosis Monitoring in Early Life (FAMILY) Study: rationale, design and baseline data of a study examining the early determinants of atherosclerosis. (partial funding by CIHR) Am Heart J 2009;158:533-539.

Search for citations for Dr. Teo on PubMed